Locations
Conditions
Treatments
Institutions
Resources
For researchers
About us
Clinical trials
Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy
Apply
Olutasidenib, Venetoclax, Azacitidine
Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy
Basic information
Step 1/5
Provide your basic information
Age
ZIP code
Back
Next step